Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.
Principal Investigator:
Sandy Feng | University of California San Francisco | San Francisco, CA
Category:
Transplantation
|
Specific Category:
Liver Transplantation
|
Status:
Complete
Learn more:
Principal Investigator:
Anil Chandraker | | Boston, MA
Kenneth Newell | Emory Healthcare | Atlanta, GA
Larry Turka | Immune Tolerance Network | Boston, MA
Category:
Transplantation
|
Specific Category:
Liver Transplantation
|
Status:
Complete
Learn more:
(
ITN524ST-CTOT-12
|
ARTIST
)
Principal Investigator:
Kenneth Newell | Emory Healthcare | Atlanta, GA
Larry Turka | Immune Tolerance Network | Boston, MA
Anil Chandraker | | Boston, MA
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Complete
Learn more:
(
ITN507ST
|
FACTOR
)
Principal Investigator:
Kenneth Newell | Emory Healthcare | Atlanta, GA
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Complete
Learn more:
(
ITN505AI
|
)
Principal Investigator:
Jack Antel | Montreal Neurological Institute | Montreal, QC
Category:
Autoimmune Disease
|
Specific Category:
Multiple Sclerosis
|
Status:
Complete
Learn more:
(
ITN504AI
|
ABBA
)
Principal Investigator:
Jorma Ilonen | University of Torku | Turku, Finland
Category:
Type 1 Diabetes
|
Specific Category:
Type 1 Diabetes
|
Status:
Complete
Learn more:
Principal Investigator:
Category:
Transplantation
|
Specific Category:
|
Status:
Complete
Learn more:
(
ITN095AI
|
DESIGNATE
)
Principal Investigator:
Stephen Gitelman | University of California San Francisco | San Francisco, CA
DESIGNATE is a clinical study to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes mellitus.
Category:
Type 1 Diabetes
|
Specific Category:
New Onset Type 1 Diabetes
|
Status:
Follow-up
Learn more:
(
ITN093AI
|
DARE-APS
)
Principal Investigator:
Doruk Erkan | Hospital for Special Surgery | New York, NY
Jason Knight | University of Michigan | Ann Arbor, MI
A study about the safety of daratumumab in patients with antiphospholipid syndrome (APS), and its effectiveness at reducing the antiphospholipid antibodies that cause APS.
Category:
Autoimmune Disease
|
Specific Category:
Primary Antiphospholipid Syndrome
|
Status:
Enrollment
Learn more:
(
ITN092AI
|
CONTROL-RA
)
Principal Investigator:
E. William St. Clair | Immune Tolerance Network | Durham, NC
The goal of CONTROL-RA is to see how the experimental study drug, VIB4920, affects control of rheumatoid arthritis (RA).
Category:
Autoimmune Disease
|
Specific Category:
Autoimmune Diseases
|
Status:
On Hold
Learn more:
No items found.
